Patients with cardiovascular disease (CVD) are at high risk of coronavirus disease 2019(COVID⁃19)and the mortality of COVID⁃19 patients with CVD were significantly increased.Currently,there is noevidence that any antiviral drugs were effective to severe acute respiratory syndrome coronavirus 2(SARS⁃CoV⁃2).In August,2020,National Health Commission issued Diagnosis and Treatment Protocol for COVID⁃19(Trial Version8)and the main antiviral drugs recommended for the treatment of COVID⁃19 are IFN⁃α,Ribavirin,Chloroquinephosphate,Arbidol,Lopinavir/ritonavir(LPV/r)and so on. All of these drugs have some adverse effects on cardio⁃vascular system. The review summarizes pharmaceutical care strategy for COVID⁃19 patients with cardiovasculardisease,and aims to provide useful guidance for pharmaceutical management and treatment of COVID⁃19 patientswith CVD.